Testing KB801 for stage 2 or 3 neurotrophic keratitis
Part of Eyes & vision clinical trials.
This trial tests whether KB801 can help heal persistent corneal defects better than a placebo. It is for people with neurotrophic keratitis (a condition where the cornea loses sensation) that has not improved with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage 2 or 3 neurotrophic keratitis (a cornea that doesn't feel pain properly).
- You have a persistent corneal defect (an open sore on the front of the eye) that hasn't healed.
- The defect must be at least 1 mm wide but no larger than 8 mm.
- You are not pregnant and agree to use birth control if needed.
- You have not had corneal transplant surgery in the past 2 years or multiple transplants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental eye drop (STSP-0902) for a condition called neurotrophic keratitis, where the cornea (the clear front part of the eye) gets scratches or sores because nerves are damaged. The drop contains a growth factor to help the eye heal. You might be eligible if you have a persistent scratch or sore on your cornea that has not improved for at least a week.
This Phase 2 trial tests BRM424 eye drops in adults with neurotrophic keratitis (a weakened, slow-healing cornea) to see if they help and are safe over 28 days. You may be able to join if your condition matches Stage 2 or Stage 3 and you meet the safety rules.
This trial tests whether a new eye drop called Lacripep can help treat neurotrophic keratitis, a rare eye condition where the cornea loses sensation and can become damaged. The study compares Lacripep to a placebo (inactive) drop to see if it improves corneal healing and vision.
This study compares two treatments for neurotrophic keratitis, a condition where the cornea (the clear front part of the eye) loses feeling due to nerve damage. One treatment is a surgery that restores nerves to the cornea, and the other is a special eye drop that helps the cornea heal. The goal is to see which treatment works better for improving eye health and vision.
This Phase 3 trial tests whether a 0.1% RGN-259 eye drop can safely improve a stubborn corneal wound in adults with neurotrophic keratopathy (nerve-related corneal healing problems). You may qualify if you still have an eye surface defect after at least a week of standard treatments, and you meet specific measurements for corneal sensitivity and vision.
This study tests an experimental eye drop (KB803) to see if it can reduce painful scrapes on the surface of the eye in people with dystrophic epidermolysis bullosa. You would be randomly assigned to receive either the study drops or a placebo (an inactive drop) for several months.
Hear when a new Neurotrophic Keratitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.